We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Bladder Cancer

Journal Scan / Research · December 22, 2020

Nivolumab and Ipilimumab for Patients With Advanced Rare Genitourinary Malignancies

Cancer

 

Additional Info

Cancer
Results of a Multicenter, Phase 2 Study of Nivolumab and Ipilimumab for Patients With Advanced Rare Genitourinary Malignancies
Cancer 2020 Nov 20;[EPub Ahead of Print], BA McGregor, MT Campbell, W Xie, S Farah, MA Bilen, AL Schmidt, GP Sonpavde, KL Kilbridge, AD Choudhury, A Mortazavi, AY Shah, AM Venkatesan, GJ Bubley, AO Siefker-Radtke, RR McKay, TK Choueiri

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading